Blue Lake Biotechnology
Chemicals & Related Products · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Riverbend Rd, Athens, Georgia, 30602...Phone Number
(706) 201-8820Revenue
<$5 MillionIndustry
About Blue Lake Biotechnology
Blue Lake Biotechnology Org Chart
Is Blue Lake Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Blue Lake Biotechnology
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Blue Lake Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Blue Lake Biotechnology recently announced quarterly report
Product Launch: Get notified when Blue Lake Biotechnology launches new products
Click to see if Blue Lake Biotechnology had a recent Job posting/layoffs
Check out if Blue Lake Biotechnology is spiking on competitors!
Funding: Get notified immidiatlly once Blue Lake Biotechnology has new funding data
Website visits: Recent activity has been detected on your website
Check if Blue Lake Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Blue Lake Biotechnology
Find 2 more new buyers
Compare Similar Companies to Blue Lake Biotechnology
Compare insights from companies similar to Blue Lake Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Blue Lake Biotechnology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Blue Lake Biotechnology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Blue Lake Biotechnology.
Blue Lake Biotechnology Tech Stack
A closer look at the technologies used by Blue Lake Biotechnology
Blue Lake Biotechnology News & Media
Preclinical Intranasal COVID-19 Vaccine Candidate Data Demonstrate Durable Immune Response and Broad Protection
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC today announced the recent publication of two preclinical studies in the Journal of Virology highlighting the durability of immune responses and broad protective efficacy of CVXGA, an intrBlue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that it will be presenting safety and immunogenicity data on BLB201, the company’s PIV5-based intranasal vaccine candidate, at the 13th International RSV Symposium, occurring March 12-15 in Iguazu, BrazBlue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced positive data from a preliminary analysis of the first 63 infants and young children enrolled in the company’s Phase 1/2a clinical study of BLB201, an intranasal vaccine candidate against RSV. BLB201 haBlue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today reported data from a 227-participant Phase 2a clinical trial demonstrating the safety, tolerability, immunogenicity, and efficacy of CVXGA, the company’s intranasal vaccine candidat
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Blue Lake Biotechnology
Blue Lake Biotechnology is focused on developing intranasal vaccines that utilize a proprietary parainfluenza virus 5 (PIV5)-based system to enhance the immune response. Their vaccines aim to prevent serious infectious diseases and protect vulnerable populations by blocking the transmission of viral infections. The company emphasizes the creation o... Read More